A customized regimen of intravitreal aflibercept for the treatment of choroidal neovascularization secondary to different chorioretinal diseases

International Journal of Retina and Vitreous

Original Article

Mayada Ali Mohamed¹  Ahmed Osama Hashem¹  Magdy Moussa²  Mahmoud Leila³ 

[1] Ophthalmology department, Faculty of Medicine, Kafr El Sheikh University, Kafr El Sheikh, Egypt;Ophthalmology department, Faculty of Medicine, Tanta University, El Bahr Street, Tanta Qism 2, Gharbia Governorate, 31111, Tanta, Egypt;Retina department, Research Institute of Ophthalmology (RIO), Giza, Egypt;

关键词: Intravitreal aflibercept;    Secondary CNV;    Customized IVA regimen;    CNV secondary to chorioretinal diseases;   

DOI  :  10.1186/s40942-023-00440-5

 received in 2022-11-05, accepted in 2022-12-31,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundTo assess the response of CNV secondary to chorioretinal diseases to IVA and to explore the adequate dosing regimen and the long-term results.MethodsA retrospective study including patients with treatment-naïve active CNV secondary to chorioretinal diseases. All patients received an initial IVA injection followed by a PRN regimen. The main outcome measures were improvement of BCVA, improvement of anatomical morphology and vascularity of the CNV on SS-OCT, and SS-OCTA, respectively, and ocular or systemic complications attributed to IVA.ResultsThe study included 17 eyes of 15 patients. Nine patients (60%) were females. The median age was 20 years. The main primary chorioretinal disease was vitelliform macular dystrophy (29%). The mean baseline BCVA was 0.16. The mean follow-up period was 15 months. Final BCVA improved by a mean of 6 lines. The CNV regressed or became inactive in all eyes. The median number of IVA injections was 2. There were no ocular or systemic complications attributed to IVA.ConclusionThe customized IVA regimen is effective in inducing long-term regression of secondary CNV and in improving BCVA. Multimodal imaging is fundamental in establishing the diagnosis of CNV, and in monitoring its response to IVA.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq298.gif

41116_2022_35_Article_IEq278.gif

41116_2022_35_Article_IEq239.gif

41116_2022_35_Article_IEq216.gif